Dec. 2, 2019—Qiagen and DiaSorin announced FDA approval of the Liaison QuantiFeron-TB Plus Test, developed by Qiagen and DiaSorin, and the U.S. launch of an automated workflow for QFT-Plus on Liaison platforms. The workflow pairs standard QuantiFeron-TB Gold Plus blood collection tubes with the Liaison QFT-Plus detection assay.
“QFT-Plus users are gaining access to the Liaison’s powerful, highly flexible automation for all throughput segments, as well as to Liaison’s broad menu of more than 100 tests,” Thierry Bernard, interim CEO of Qiagen and senior vice president, head of the molecular diagnostics business, said in a company press release.
The Liaison’s workflow for QFT-Plus was introduced in Europe in 2018 and is planned for China in 2020. Additional tests based on QuantiFeron technology are planned for adaptation to the Liaison platforms.